Abstract:BACKGROUND:No established treatment algorithm exists for patients with schizophrenia. Whether switching antipsychotics or early use of clozapine improves outcome in (first-episode) schizophrenia is unknown.METHODS:This three-phase study was done in 27 centres, consisting of general hospitals and psychiatric specialty clinics, in 14 European countries and Israel. Patients aged 18-40 years who met criteria of the DSM-IV for schizophrenia, schizophreniform disorder, or schizoaffective disorder were treated for 4 weeks with up to 800 mg/day amisulpride orally in an open-label design (phase 1). Patients who did not meet symptomatic remission criteria at 4 weeks were randomly assigned to continue amisulpride or switch to olanzapine (≤20 mg/day) during a 6-week double-blind phase, with patients and staff masked to treatment allocation (phase 2). Randomisation was done online by a randomisation website; the application implemented stratification by site and sex, and applied the minimisation method for randomisation. Patients who were not in remission at 10 weeks were given clozapine (≤900 mg/day) for an additional 12 weeks in an open-label design (phase 3). The primary outcome was the number of patients who achieved symptomatic remission at the final visits of phases 1, 2, and 3, measured by intention-to-treat analysis. Data were analysed with a generalised linear mixed model, with a logistic link and binomial error distribution. This trial is registered with ClinicalTrials.gov, number NCT01248195, and closed to accrual.FINDINGS:Between May 26, 2011, and May 15, 2016, we recruited 481 participants who signed informed consent. Of the 446 patients in the intention-to-treat sample, 371 (83%) completed open-label amisulpride treatment, and 250 (56%) achieved remission after phase 1. 93 patients who were not in remission continued to the 6-week double-blind switching trial, with 72 (77%) patients completing the trial (39 on olanzapine and 33 on amisulpride); 15 (45%) patients on amisulpride versus 17 (44%) on olanzapine achieved remission (p=0·87). Of the 40 patients who were not in remission after 10 weeks of treatment, 28 (70%) started on clozapine; 18 (64%) patients completed the 12-week treatment, and five (28%) achieved remission. The number of serious adverse events did not differ between the treatment arms in phase 2: one patient on olanzapine was admitted to hospital because of an epileptic seizure, and one patient on amisulpride was admitted to hospital twice because of exacerbations of psychotic symptoms. Over the course of the trial, two serious suicide attempts were reported.INTERPRETATION:For most patients in the early stages of schizophrenia, symptomatic remission can be achieved using a simple treatment algorithm comprising the sequential administration of amisulpride and clozapine. Since switching to olanzapine did not improve outcome, clozapine should be used after patients fail a single antipsychotic trial-not until two antipsychotics have been tried, as is the current recommendation.FUNDING:European Commission Seventh Framework Program.

Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

COMT, 5-HTR2A, and SLC6A4 Mrna Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association with Treatment Outcomes

Association of Telomere Length and Mitochondrial DNA Copy Number with Risperidone Treatment Response in First-Episode Antipsychotic-Naïve Schizophrenia

Gut Microbial Biomarkers for the Treatment Response in First-Episode, Drug-Naïve Schizophrenia: a 24-Week Follow-Up Study

Association of Complement and Coagulation Pathway Proteins with Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial

Stratification and prediction of remission in first-episode psychosis patients OPTIMISE

Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis

Incidence and factors associated of early non-response in first-treatment and drug-naïve patients with schizophrenia: a real-world study

Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses

Predictive Biomarkers for Antipsychotic Treatment Response in Early Phase of Schizophrenia: Multi-Omic Measures Linking Subcortical Covariant Network, Transcriptomic Signatures, and Peripheral Epigenetics

Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial

Combining machine learning algorithms for prediction of antidepressant treatment response

Predictors of Antipsychotic Treatment Response in Patients with First Episode Schizophrenia, Schizoaffective, and Schizophreniform Disorders

Amisulpride and Olanzapine Followed by Open-Label Treatment with Clozapine in First-Episode Schizophrenia and Schizophreniform Disorder (optimise): a Three-Phase Switching Study.

Enhanced Baseline Activity in the Left Ventromedial Putamen Predicts Individual Treatment Response in Drug-Naive, First-Episode Schizophrenia: Results from Two Independent Study Samples.

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction

Longitudinal Trajectory Analysis of Antipsychotic Response in Patients with Schizophrenia: 6-Week, Randomised, Open-Label, Multicentre Clinical Trial

The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: a Systematic Review.

Predicting treatment resistance in positive and negative symptom domains from first episode psychosis: Development of a clinical prediction model

Therapeutic Outcomes Wide Association Scan of Different Antipsychotics in Patients with Schizophrenia: Randomized Clinical Trials and Multi-Ancestry Validation